Germany's Drug Shortages Leave Millions of Patients Without Critical Medications in 2025

German pharmacies are facing severe drug shortages in 2025, with over 1,500 supply bottlenecks reported. Over 1,514 shortage reports were logged this year, covering 1,041 distinct supply issues. Consumer reports indicate that antibiotics alone accounted for 85 of these reports, with shortages lasting an average of 122 days—affecting around 2.2 million patients. Lipid-lowering agents also saw 89 shortage reports, each lasting roughly 156 days and impacting another two million people.

Psychotropic drugs have been hit particularly hard. Antipsychotics faced 173 shortage reports, with each lasting about 230 days and affecting one million patients. Antidepressants followed closely, with 130 reports and an average shortage duration of 107 days, also impacting around one million individuals. Shortages of salbutamol and antiepileptic drugs have raised additional concerns due to the lack of readily available alternatives.

The problem stems partly from Germany's reliance on global supply chains, especially in Asia, where many drugs and active ingredients are produced. Disruptions in this region have left the country's pharmaceutical supply vulnerable. While the 2023 Shortages Act aimed to address these issues, health insurers report that no structural improvements have yet materialised. In response, proposals for an early-warning system have emerged, designed to alert German stakeholders quickly about major production failures in Asia.

The ongoing shortages have exposed gaps in Germany's drug supply system, leaving patients without vital treatments for months. Without further intervention, the reliance on unstable global production chains could prolong these challenges. Authorities are now considering new measures to prevent future disruptions and ensure a steadier flow of essential medications.